Navigation Links
GlaxoSmithKline and Cellzome Announce Major Strategic Alliance
Date:9/10/2008

Kinobeads(TM) Technology to Identify a New Generation of Drug Candidates

for Inflammatory Diseases

LONDON and CAMBRIDGE, England and PHILADELPHIA and HEIDELBERG, Germany, September 10 /PRNewswire/ -- Cellzome Inc. and GlaxoSmithKline (LSE & NYSE: GSK) announce the signing of a worldwide strategic alliance to discover, develop and market novel kinase-targeted therapeutics to treat inflammatory diseases.

The alliance gives GSK access to Cellzome's significant expertise in identifying and developing selective kinase inhibitors and its proprietary Kinobeads(TM) technology which, by screening compounds in a physiological setting, is designed to improve the predictability of these drug candidates' performance in clinical testing. Kinases are key molecular switches in cellular signaling events with a central role in many inflammatory responses and selective inhibitors offer a different approach to therapeutic intervention in diseases such as rheumatoid arthritis or multiple sclerosis.

Under the agreement GSK has exclusive options to license drug candidates from Cellzome's kinase programs directed against four identified targets, and three additional targets to be jointly identified by both parties. In the alliance, Cellzome will utilize its proprietary Kinobeads(TM) technology to discover novel small molecule inhibitors of these targets, and then will develop the most promising product candidates through to completion of a clinical proof of concept trial, unless GSK elects to exercise its option earlier. Cellzome is eligible to receive success-based milestones from GSK as product candidates are advanced. Upon Cellzome's achievement of clinical proof of concept for a product candidate for a particular kinase target, GSK would have an exclusive option to license all product candidates from that program. GSK would then assume full responsibility for further clinical development and commercialization on a worldwide basis. Ce
'/>"/>

SOURCE Cellzome Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GlaxoSmithKline Offers New Purchasing Options to Help Employers Overcome Barriers to Pandemic Stockpiling of Relenza(R)
2. GlaxoSmithKline To Post Quarterly US Grants Report
3. GlaxoSmithKline - Q2 Results and Strategy Update - Interview with CEO
4. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
5. CDC Immunization Advisory Committee Recommends Two New Pediatric Vaccines from GlaxoSmithKline
6. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
7. GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections
8. GlaxoSmithKline Signs Licensing Agreement With Compendia Bioscience
9. GlaxoSmithKline Named A Top Employer for Promoting Healthy Lifestyles
10. GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals
11. GlaxoSmithKline to Acquire Sirtris Pharmaceuticals, a World Leader in Sirtuin Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Crystal Diagnostics (CDx) Xpress ... it has received AOAC-PTM Certifications for the six non-O157 Shiga ... O145; collectively referred to as STEC or the “Big-6”) as ... forming unit (cfu) per 325 g of raw ground beef ...
(Date:1/22/2015)... zFlo Motion , a US leader ... exciting product from a new partner. STT-Systems has ... past 15 years, with offerings in the optical-motion capture, 3D ... system (inertial measurement unit), iSen, is opening eyes around the ...
(Date:1/22/2015)... 22, 2015 Controlled Substance Compliance Services ... helps companies check the legal requirements around using controlled ... China. , As their international operations expand and ... software solutions built as a result of the first ...
(Date:1/22/2015)... 22, 2015 Diagenode, Inc., a ... the Bioruptor® and complete solutions for epigenetics research, ... immunoprecipitation, alleviating the need for manual processing. The ... for ChIP of histones or transcription factors and ...
Breaking Biology Technology:Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 23D Motion Capture Just Got Easy 2Global Compliance Service for Controlled Substances to Expand to China 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2
... of Roche Diagnostics, North America, Has 25 Years of Life ... Sciences Industry ... KOOL ), a leading supplier of innovative products that,process and store ... Chief Executive Officer, Roche Diagnostics,Corporation, North America, has been named to ...
... with Company Estimates Highlighted by 11% Discovery ... Products and Services Growth -, ... ) today reported second quarter financial,results for 2008. Revenues were $34.0 ... quarter of $35.3 million. Revenues were impacted,by a $3.5 million decline ...
... ISLAND, S.C., Aug. 6 Denham Capital,("Denham") ... to $60 million in VitAG,Corporation ("VitAG"). VitAG ... fertilizer product capable of competing with and,outperforming ... of multiple biosolids-to-fertilizer manufacturing plants., "Denham,s ...
Cached Biology Technology:ThermoGenesis Names Tiffany Olson to Board of Directors 2ThermoGenesis Names Tiffany Olson to Board of Directors 3Caliper Life Sciences Reports Second Quarter 2008 Results 2Caliper Life Sciences Reports Second Quarter 2008 Results 3Caliper Life Sciences Reports Second Quarter 2008 Results 4Caliper Life Sciences Reports Second Quarter 2008 Results 5Caliper Life Sciences Reports Second Quarter 2008 Results 6Caliper Life Sciences Reports Second Quarter 2008 Results 7Caliper Life Sciences Reports Second Quarter 2008 Results 8Caliper Life Sciences Reports Second Quarter 2008 Results 9Denham Capital to Invest $60 Million in VitAG, Recycler of Municipal Biosolids 2
(Date:1/22/2015)... YORK , Jan. 22, 2015   EyeLock, Inc. , ... it has appointed Steve Gerber to the new ... will be responsible for leading development of mobile platforms and ... years of success and innovation in the semiconductor industry to ...
(Date:12/22/2014)... 2014  The 2014 Holiday Season may be the brightest ... reports that the long anticipated floodgates for consumer biometrics ... for smart phones, tablets, and wearable mobile devices that ... billion users with nearly 4.8 billion biometric devices by ...
(Date:12/17/2014)... 15, 2014 Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ... Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology ... http://photos.prnewswire.com/prnh/20130307/600769 Based on a ... introduces for the first time a fingerprint sensor in ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... organic farming becomes more common, methods to identify ... a recent study in Journal of Environmental Quality, ... if non-organic, synthetic fertilizers were used on sweet ... de Investigacin y Desarrollo Agrario y Agrario y ...
... REM sleep deprivation procedure reduces cell proliferation in the ... of rats, according to a study published in the ... study, authored by Dennis McGinty, PhD, of the V.A. ... rats. REM sleep deprivation was achieved by a ...
... of Southern California have developed a prostate cancer vaccine ... of young mice genetically predestined to develop the disease. ... they suggest the same strategy might work for men ... potential diagnostic indicator of prostate cancer. By ...
Cached Biology News:Is it organic or not? 24 days of REM sleep deprivation contributes to a reduction of cell proliferation in rats 2Prostate cancer: Watchful wait or vaccinate? 2Prostate cancer: Watchful wait or vaccinate? 3
Rabbit Anti-conjugated Agmatine Polyclonal Antibody...
ABCA1 Immunogen: Mouse ABCA1-expressing HeLa stable transfectants. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... ADAMTS16 ( Abpromise for all ... Synthetic peptide based on the ... the amino acid sequence is proprietary) ... 170690 SWISS Protein ...
Goat polyclonal to SART3 ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSNADFAKLFLRK, corresponding to C terminal amino acids 951-963 of Human SART3 Entrez Gene ID: 9...
Biology Products: